TGTX — TG THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About TG THERAPEUTICS INC (TGTX)
TG THERAPEUTICS INC (TGTX) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $81M. Across recent filings, tracked investors recorded 1 new positions, 1 increased, 1 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in TGTX
How many top investors track TGTX
A small number of top investors own this.
TGTX Ownership Composition
How TG THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other93.4%
- Hedge Funds6.6%
Tracked investors reporting TGTX
- Ken GriffinMar 31, 2026Citadel AdvisorsShares2.4MValue$81.2M% Portfolio0.01%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares160.9KValue$5.3M% Portfolio0.00%
- Ray DalioMar 31, 2026Bridgewater AssociatesShares311.4KValue$10.3M% Portfolio0.05%
- Steve CohenDec 31, 2025Point72 Asset ManagementShares231.4KValue$6.9M% Portfolio0.01%
Recent activity
- Reduced$10.3M(-33.72%)May 15, 2026
- Increased$14M(37.32%)Feb 13, 2026
- New$12.4MNov 13, 2025
Frequently asked questions
- How many institutional investors hold TGTX?
- 4 tracked institutional investors disclosed a position in TGTX (TG THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of TGTX?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in TGTX, valued at $81M.
- Did institutional ownership of TGTX increase or decrease?
- Across recent 13F filings, tracked investors recorded 1 new positions, 1 increased, 1 reduced, and 0 fully exited TGTX.
- Where does this TGTX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.